Wei V Zheng
Overview
Explore the profile of Wei V Zheng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
121
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zheng W, Li Y, Xu Y, Lu D, Zhou T, Li D, et al.
Cell Cycle
. 2022 Feb;
21(9):934-947.
PMID: 35188065
There are two main types of growth hormone (GH) in the circulatory system. One is 22 kD-GH, which is the predominant isoform in the circulating system, 90% GH is present...
12.
microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3
Li Y, Zhou T, Cheng X, Li D, Zhao M, Zheng W
Bioengineered
. 2022 Feb;
13(3):4730-4743.
PMID: 35184646
Programmed death ligand 1 (PD-L1) plays an essential role in the development or progression of hepatocellular carcinoma (HCC). MicroRNAs (miRNAs) are small RNA molecules that regulate gene expression during normal...
13.
Li Y, Cheng X, Chen Y, Zhou T, Li D, Zheng W
Am J Transl Res
. 2022 Jan;
13(12):13423-13437.
PMID: 35035685
Objective: To explore whether METTL3 was involved in the pathogenesis of hepatocellular carcinoma (HCC) by modulating the m6A level of USP7. Methods: We performed qRT-PCR and western blot assays to...
14.
Cheng X, Li D, Qi T, Sun J, Zhou T, Zheng W
Sci Rep
. 2022 Jan;
12(1):211.
PMID: 34997064
Although the overall survival of hepatocellular carcinoma (HCC) patients has been significantly improved, prognostic clinical evaluation remains a substantial problem owing to the heterogeneity and complexity of tumor. A reliable...
15.
Li D, Zhou T, Li Y, Xu Y, Cheng X, Chen J, et al.
Aging (Albany NY)
. 2022 Jan;
14(1):368-388.
PMID: 34990401
Hepatocellular carcinoma (HCC) is one of the most death-related cancers worldwide. Identifying cancer-associated genes and uncovering the vital molecular mechanisms of HCC progression contribute greatly to the prognosis and novel...
16.
Zheng W, Li Y, Cheng X, Xu Y, Zhou T, Li D, et al.
J Cell Mol Med
. 2021 Dec;
26(3):840-854.
PMID: 34970843
At present, liver fibrosis is a major challenge of global health. When hepatocyte regeneration cannot compensate for hepatocyte death, it will develop into liver fibrosis in chronic liver disease. Initially,...
17.
Hu Z, Zhang C, Wang D, Gao S, Ong S, Wang Y, et al.
Front Cell Dev Biol
. 2021 Dec;
9:771248.
PMID: 34869366
CRISPR/Cas9 nucleases hold great potential for gene therapy, but they frequently induce unwanted off-target cleavage. We previously developed a GFP activation assay for detection of DNA cleavage in cells. Here,...
18.
Zheng W, Li Y, Xu Y, Zhou T, Li D, Cheng X, et al.
Biofactors
. 2021 Dec;
48(1):67-85.
PMID: 34866251
Growth hormone (GH) exhibited the important biological activities in the mesenchymal stem cell (MSCs). However, the cellular behavior and properties of GH/GHR in MSCs remain unclear. A series of experiments...
19.
Zhou X, Jiao L, Qian Y, Dong Q, Sun Y, Zheng W, et al.
Biomolecules
. 2021 Jun;
11(5).
PMID: 34068552
Strategies boosting both innate and adaptive immunity have great application prospects in cancer immunotherapy. Antibodies dual blocking the innate checkpoint CD47 and adaptive checkpoint PD-L1 or TIGIT could achieve durable...